Gabapentin
Product Images NDC 51407-047

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 51407-047). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Golden State Medical Supply, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

51407 047 90lb Gabapentin 100 mg Capsules Rev Nov 2020 Pmg Nov 2020 12 17 2020

Gabapentin 100 mg capsules, USP, label from Golden State Medical Supply, Inc. The label indicates a package size of 90 capsules with NDC 51407-047-90. It includes storage instructions and a note to see the package insert for dosage information, marked Rx only.*

FDA Label Image

51407 048 90lb Gabapentin 300 mg Capsules Rev Nov 2020 Pmg Nov 2020 12 31 2020

Packaging label for Gabapentin capsules, USP 300 mg by Golden State Medical Supply, Inc. The label shows an NDC number 51407-048-90 and indicates a bottle of 90 capsules. It includes storage instructions and a note to see the package insert for dosage information, with "Rx only" clearly marked.*

FDA Label Image

51407 049 90lb Gabapentin 400 mg Capsules Rev Nov 2020 Pmg Nov 2020 12 17 2020

Label for Gabapentin capsules, USP, 400 mg strength, in a package containing 90 capsules. The label displays the NDC number 51407-049-90 and indicates it is for prescription use only. Manufactured by Golden State Medical Supply, Inc.*

FDA Label Image

Figure 1 (Image 01)

A line graph showing mean pain score over 8 weeks comparing placebo and Gabapentin at 3600 mg/day. The x-axis represents time in weeks from baseline to week 8, divided into a 4-week dose titration period and a 4-week fixed dose period. The y-axis represents mean pain score from 0 to 10. Gabapentin shows a decreasing mean pain score over time, while placebo remains relatively stable.*

FDA Label Image

Figure 2 (Image 02)

A line graph showing mean pain scores over a 7-week period comparing placebo, Gabapentin 1800 mg/day, and Gabapentin 2400 mg/day. The graph includes a 3-week dose titration period followed by a 4-week fixed dose period, with pain scores decreasing over time for both Gabapentin doses compared to placebo.*

FDA Label Image

Figure 3 (Image 03)

A bar chart titled 'Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies' showing results from two studies comparing placebo (PBO) and Gabapentin (GBP) at different doses. Study 1 shows 12% for placebo and 29% for GBP 3600. Study 2 shows 14% for placebo, 32% for GBP 1800, and 34% for GBP 2400, with significance levels indicated by p-values.*

FDA Label Image

Cockcroft And Gault Equation (Image 04)

An equation diagram illustrating the calculation of creatinine clearance (CLCr) based on age, weight, serum creatinine, and a gender factor for female patients. The formula shows how to adjust dosage by renal function.*

FDA Label Image

Gabapentin Structural Formula (Image 05)

Chemical structure diagram of gabapentin, showing a cyclohexane ring attached to a central carbon bonded to an amino group (CH2NH2) and a carboxyl group (CH2CO2H). This represents the active ingredient gabapentin.*

FDA Label Image

Figure 4. Responder Rate In Patients Receiving Gabapentin Expressed As A Difference From Placebo By Dose And Study: Adjunctive Therapy Studies In Patients ≥12 Years Of Age With Partial Seizures (Image 09)

A scatter plot chart showing the percentage difference on the y-axis against daily dose in milligrams on the x-axis for Gabapentin from three different studies labeled as Study a, Study b, and Study c. The doses range from 600 mg to 1800 mg, with data points plotted for each study at various dose levels.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.